Dr. Hammers Discusses Immunotherapy in RCC – OncLive
OncLive |
Dr. Hammers Discusses Immunotherapy in RCC
OncLive Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses immunotherapy in renal cell carcinoma (RCC). In November 2015, nivolumab (Opdivo) was approved by the FDA for the second-line treatment of … |
